Selected research
Market Structure
Global Intercellular Adhesion Molecule 1 Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Intercellular Adhesion Molecule 1 market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Intercellular Adhesion Molecule 1 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Intercellular Adhesion Molecule 1 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Intercellular Adhesion Molecule 1 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Intercellular Adhesion Molecule 1 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Intercellular Adhesion Molecule 1 include RXi Pharmaceuticals Corp, China Medical System Holdings Ltd and Atlantic Healthcare Plc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Intercellular Adhesion Molecule 1 market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Intercellular Adhesion Molecule 1 and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Intercellular Adhesion Molecule 1 sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Intercellular Adhesion Molecule 1 market size, projected growth trends, production technologies, key applications, and end-use industries.
Intercellular Adhesion Molecule 1 Segment by Company
RXi Pharmaceuticals Corp
China Medical System Holdings Ltd
Atlantic Healthcare Plc
Intercellular Adhesion Molecule 1 Segment by Type
CMS-024
DNP-003
MS-553
Others
Intercellular Adhesion Molecule 1 Segment by Application
Genito Urinary System and Sex Hormones
Dermatology
Crohn's Disease
Others
Intercellular Adhesion Molecule 1 Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Intercellular Adhesion Molecule 1 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Intercellular Adhesion Molecule 1 and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Intercellular Adhesion Molecule 1.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Intercellular Adhesion Molecule 1 market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Intercellular Adhesion Molecule 1 manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Intercellular Adhesion Molecule 1 in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Intercellular Adhesion Molecule 1 in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- CMS-024
- DNP-003
- MS-553
- Others
Applications
- Genito Urinary System and Sex Hormones
- Dermatology
- Crohn's Disease
- Others
Companies covered
- RXi Pharmaceuticals Corp
- China Medical System Holdings Ltd
- Atlantic Healthcare Plc
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Intercellular Adhesion Molecule 1 Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Intercellular Adhesion Molecule 1 Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Intercellular Adhesion Molecule 1 Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Intercellular Adhesion Molecule 1 Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Intercellular Adhesion Molecule 1 Market Dynamics
- 2.1 Intercellular Adhesion Molecule 1 Industry Trends
- 2.2 Intercellular Adhesion Molecule 1 Industry Drivers
- 2.3 Intercellular Adhesion Molecule 1 Industry Opportunities and Challenges
- 2.4 Intercellular Adhesion Molecule 1 Industry Restraints
3 Intercellular Adhesion Molecule 1 Market by Manufacturers
- 3.1 Global Intercellular Adhesion Molecule 1 Revenue by Manufacturers (2021-2026)
- 3.2 Global Intercellular Adhesion Molecule 1 Sales by Manufacturers (2021-2026)
- 3.3 Global Intercellular Adhesion Molecule 1 Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Intercellular Adhesion Molecule 1 Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Intercellular Adhesion Molecule 1 Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Intercellular Adhesion Molecule 1 Manufacturers, Product Type & Application
- 3.7 Global Intercellular Adhesion Molecule 1 Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Intercellular Adhesion Molecule 1 Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Intercellular Adhesion Molecule 1 Players Market Share by Revenue in 2025
- 3.8.3 2025 Intercellular Adhesion Molecule 1 Tier 1, Tier 2, and Tier 3
4 Intercellular Adhesion Molecule 1 Market by Type
- 4.1 Intercellular Adhesion Molecule 1 Type Introduction
- 4.1.1 CMS-024
- 4.1.2 DNP-003
- 4.1.3 MS-553
- 4.1.4 Others
- 4.2 Global Intercellular Adhesion Molecule 1 Sales by Type
- 4.2.1 Global Intercellular Adhesion Molecule 1 Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Intercellular Adhesion Molecule 1 Sales by Type (2021-2032)
- 4.2.3 Global Intercellular Adhesion Molecule 1 Sales Market Share by Type (2021-2032)
- 4.3 Global Intercellular Adhesion Molecule 1 Revenue by Type
- 4.3.1 Global Intercellular Adhesion Molecule 1 Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Intercellular Adhesion Molecule 1 Revenue by Type (2021-2032)
- 4.3.3 Global Intercellular Adhesion Molecule 1 Revenue Market Share by Type (2021-2032)
5 Intercellular Adhesion Molecule 1 Market by Application
- 5.1 Intercellular Adhesion Molecule 1 Application Introduction
- 5.1.1 Genito Urinary System and Sex Hormones
- 5.1.2 Dermatology
- 5.1.3 Crohn's Disease
- 5.1.4 Others
- 5.2 Global Intercellular Adhesion Molecule 1 Sales by Application
- 5.2.1 Global Intercellular Adhesion Molecule 1 Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Intercellular Adhesion Molecule 1 Sales by Application (2021-2032)
- 5.2.3 Global Intercellular Adhesion Molecule 1 Sales Market Share by Application (2021-2032)
- 5.3 Global Intercellular Adhesion Molecule 1 Revenue by Application
- 5.3.1 Global Intercellular Adhesion Molecule 1 Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Intercellular Adhesion Molecule 1 Revenue by Application (2021-2032)
- 5.3.3 Global Intercellular Adhesion Molecule 1 Revenue Market Share by Application (2021-2032)
6 Global Intercellular Adhesion Molecule 1 Sales by Region
- 6.1 Global Intercellular Adhesion Molecule 1 Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Intercellular Adhesion Molecule 1 Sales by Region (2021-2032)
- 6.2.1 Global Intercellular Adhesion Molecule 1 Sales by Region (2021-2026)
- 6.2.2 Global Intercellular Adhesion Molecule 1 Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Intercellular Adhesion Molecule 1 Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Intercellular Adhesion Molecule 1 Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Intercellular Adhesion Molecule 1 Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Intercellular Adhesion Molecule 1 Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Intercellular Adhesion Molecule 1 Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Intercellular Adhesion Molecule 1 Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Intercellular Adhesion Molecule 1 Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Intercellular Adhesion Molecule 1 Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Intercellular Adhesion Molecule 1 Revenue by Region
- 7.1 Global Intercellular Adhesion Molecule 1 Revenue by Region
- 7.1.1 Global Intercellular Adhesion Molecule 1 Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Intercellular Adhesion Molecule 1 Revenue by Region (2021-2026)
- 7.1.3 Global Intercellular Adhesion Molecule 1 Revenue by Region (2027-2032)
- 7.1.4 Global Intercellular Adhesion Molecule 1 Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Intercellular Adhesion Molecule 1 Revenue (2021-2032)
- 7.2.2 North America Intercellular Adhesion Molecule 1 Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Intercellular Adhesion Molecule 1 Revenue (2021-2032)
- 7.3.2 Europe Intercellular Adhesion Molecule 1 Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Intercellular Adhesion Molecule 1 Revenue (2021-2032)
- 7.4.2 Asia-Pacific Intercellular Adhesion Molecule 1 Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Intercellular Adhesion Molecule 1 Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Intercellular Adhesion Molecule 1 Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 RXi Pharmaceuticals Corp
- 8.1.1 RXi Pharmaceuticals Corp Company Information
- 8.1.2 RXi Pharmaceuticals Corp Business Overview
- 8.1.3 RXi Pharmaceuticals Corp Intercellular Adhesion Molecule 1 Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 RXi Pharmaceuticals Corp Intercellular Adhesion Molecule 1 Product Portfolio
- 8.1.5 RXi Pharmaceuticals Corp Recent Developments
- 8.2 China Medical System Holdings Ltd
- 8.2.1 China Medical System Holdings Ltd Company Information
- 8.2.2 China Medical System Holdings Ltd Business Overview
- 8.2.3 China Medical System Holdings Ltd Intercellular Adhesion Molecule 1 Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 China Medical System Holdings Ltd Intercellular Adhesion Molecule 1 Product Portfolio
- 8.2.5 China Medical System Holdings Ltd Recent Developments
- 8.3 Atlantic Healthcare Plc
- 8.3.1 Atlantic Healthcare Plc Company Information
- 8.3.2 Atlantic Healthcare Plc Business Overview
- 8.3.3 Atlantic Healthcare Plc Intercellular Adhesion Molecule 1 Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Atlantic Healthcare Plc Intercellular Adhesion Molecule 1 Product Portfolio
- 8.3.5 Atlantic Healthcare Plc Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Intercellular Adhesion Molecule 1 Value Chain Analysis
- 9.1.1 Intercellular Adhesion Molecule 1 Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Intercellular Adhesion Molecule 1 Production Mode & Process
- 9.2 Intercellular Adhesion Molecule 1 Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Intercellular Adhesion Molecule 1 Distributors
- 9.2.3 Intercellular Adhesion Molecule 1 Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst